New class of KRAS inhibitors shows promise at shrinking NF1 nerve tumours

Author: ecancer
Published On: 11//8/26

A scientist at Cincinnati Children’s who has hunted for decades for ways to shrink the painful and disfiguring nerve tumours caused by neurofibromatosis type 1 (NF1) has made a new breakthrough in the quest.

Nancy Ratner, PhD, and a team of nine co-authors, are reporting that a novel class of medications – known as KRAS inhibitors – shows at least as much potential as FDA-approved MEK inhibitors shrinking NF1 tumours.

Detailed findings, based on tests involving a closely similar line of mice that helped drive early-stage research for MEK inhibitors, were published Sept. 2, 2026, in the journal Science Advances.

“These findings provide compelling preclinical evidence for KRAS inhibition as a novel treatment strategy for NF1-associated neurofibromas,” Ratner says.

Cincinnati Children’s research helps drive improved NF1 treatments 

In recent years, medicines known as MEK inhibitors have helped reduce NF1 tumour sizes for many patients.

Two MEK inhibitors– selumetinib (2020) and mirdametinib (2025) – were approved by the FDA in significant part thanks to Ratner’s early research.

Her team developed a crucial mouse model that mimicked the human disease well enough to show the potential value of MEK inhibitors.

Ratner has worked ever since to further understand the biology of NF1 tumours and search for even more effective treatments.

In fact, she was recognised in 2024 by the NF Forward foundation for her career-long dedication to NF1 research.

Now, her team has achieved a new level of progress against these nerve tumours.

Read More

 

Find upcoming NF Events            Donate to NF          Stay iNFormed 


Want to view archived newsletters? Click Here!

Newsletter

Sign up to receive the latest neurofibromatosis news and information in your inbox!

Subscribe

Categories

Have a story you'd like to share with the NF community? Click Here!